Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).
Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E 3rd, Sugarbaker DJ.
Elias AD, et al. Among authors: strauss g.
Lung Cancer. 1997 May;17(1):147-61. doi: 10.1016/s0169-5002(97)00658-2.
Lung Cancer. 1997.
PMID: 9194034
Clinical Trial.
Continuous infusion cisplatin 25 mg/m2/day 1-5, 5-fluorouracil 800 mg/m2/day 2-5, and high-dose leukovorin 500 mg/m2/day 1-5 (PFL) given every 4 weeks achieved a 41% response rate in metastatic NSCLC (Lynch TJ, Kalish LA, Kass F, Strauss G, Elias A, Skarin A, Shulma …
Continuous infusion cisplatin 25 mg/m2/day 1-5, 5-fluorouracil 800 mg/m2/day 2-5, and high-dose leukovorin 500 mg/m2/day 1-5 (PFL) given eve …